Gilenya's Impact on Cognitive Function and Thalamic Volumes

Completed · Not applicable

Conditions studied: Multiple Sclerosis

In brief

This evaluation will be a one-year feasibility study to characterize the neuroprotective benefits of Gilenya and its effects on cognition and grey matter volumes. The study will enroll 15 patients with relapsing-remitting multiple sclerosis being treated with Gilenya and 5 healthy controls. Each participant will undergo a battery of neurometric testing at baseline, six months, and one year. In addition, patients will undergo high-field 7T MRI at the same time points.

Key facts

Study ID
NCT03243721
Run by
The Cleveland Clinic
People needed
20
Starts
2017-10-20
Expected to finish
2019-11-12
Last updated by the study team
2021-09-05

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.